410 related articles for article (PubMed ID: 29270757)
1. Three dimensional orbital magnetic resonance T2-mapping in the evaluation of patients with Graves' ophthalmopathy.
Hou K; Ai T; Hu WK; Luo B; Wu YP; Liu R
J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):938-942. PubMed ID: 29270757
[TBL] [Abstract][Full Text] [Related]
2. Orbital magnetic resonance imaging combined with clinical activity score can improve the sensitivity of detection of disease activity and prediction of response to immunosuppressive therapy for Graves' ophthalmopathy.
Tachibana S; Murakami T; Noguchi H; Noguchi Y; Nakashima A; Ohyabu Y; Noguchi S
Endocr J; 2010; 57(10):853-61. PubMed ID: 20733265
[TBL] [Abstract][Full Text] [Related]
3. Application of Multiparameter Quantitative Magnetic Resonance Imaging in the Evaluation of Graves' Ophthalmopathy.
Li Z; Luo Y; Feng X; Zhang Q; Zhong Q; Weng C; Chen Z; Shen J
J Magn Reson Imaging; 2023 Oct; 58(4):1279-1289. PubMed ID: 36780178
[TBL] [Abstract][Full Text] [Related]
4. Baseline Volumetric T2 Relaxation Time Histogram Analysis: Can It Be Used to Predict the Response to Intravenous Methylprednisolone Therapy in Patients With Thyroid-Associated Ophthalmopathy?
Liu P; Luo B; Chen L; Wang QX; Yuan G; Jiang GH; Zhang J
Front Endocrinol (Lausanne); 2021; 12():614536. PubMed ID: 33716970
[TBL] [Abstract][Full Text] [Related]
5. [Injection of methylprednisolone directly into the extraocular muscles of eyes with disturbed motility secondary to Graves' ophthalmopathy. Preliminary report].
Mikita A; Mariak Z; Myśliwiec J
Endokrynol Pol; 2005; 56(2):168-73. PubMed ID: 16335685
[TBL] [Abstract][Full Text] [Related]
6. Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy.
De Bellis A; Bizzarro A; Conte M; Coronella C; Solimeno S; Perrino S; Sansone D; Guaglione M; Wall JR; Bellastella A
Clin Endocrinol (Oxf); 2003 Sep; 59(3):388-95. PubMed ID: 12919164
[TBL] [Abstract][Full Text] [Related]
7. Quantitative assessment of extraocular muscles in Graves' ophthalmopathy using T1 mapping.
Zhu H; Zou M; Wu D; Li B; Su Y; Li Y; Hong S; Yang Z
Eur Radiol; 2023 Dec; 33(12):9074-9083. PubMed ID: 37466707
[TBL] [Abstract][Full Text] [Related]
8. Application of Magnetic Resonance Imaging in the Evaluation of Disease Activity in Graves' Ophthalmopathy.
Liu X; Su Y; Jiang M; Fang S; Huang Y; Li Y; Zhong S; Wang Y; Zhang S; Wu Y; Sun J; Fan X; Zhou H
Endocr Pract; 2021 Mar; 27(3):198-205. PubMed ID: 33658136
[TBL] [Abstract][Full Text] [Related]
9. T2 mapping histogram at extraocular muscles for predicting the response to glucocorticoid therapy in patients with thyroid-associated ophthalmopathy.
Hu H; Chen HH; Chen W; Wu Q; Chen L; Zhu H; Xu XQ; Shi HB; Wu FY
Clin Radiol; 2021 Feb; 76(2):159.e1-159.e8. PubMed ID: 33010933
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of Grave's ophthalmopathy with high doses of corticosteroids].
Cirić J; Zarković M; Stojanović M; Pepenezić Z; Randjelović G; Gligorović M; Trbojević B; Drezgić M; Nesović M
Srp Arh Celok Lek; 2000; 128(5-6):179-83. PubMed ID: 11089418
[TBL] [Abstract][Full Text] [Related]
11. Graves' ophthalmopathy: eye muscle involvement in patients with diplopia.
Nagy EV; Toth J; Kaldi I; Damjanovich J; Mezosi E; Lenkey A; Toth L; Szabo J; Karanyi Z; Leovey A
Eur J Endocrinol; 2000 Jun; 142(6):591-7. PubMed ID: 10832104
[TBL] [Abstract][Full Text] [Related]
12. The application of temperature measurement of the eyes by digital infrared thermal imaging as a prognostic factor of methylprednisolone pulse therapy for Graves' ophthalmopathy.
Shih SR; Li HY; Hsiao YL; Chang TC
Acta Ophthalmol; 2010 Aug; 88(5):e154-9. PubMed ID: 20553230
[TBL] [Abstract][Full Text] [Related]
13. Improvement of the MRI and clinical features of Asian Graves' ophthalmopathy by radiation therapy with steroids.
Ma Z; Ozaki H; Ishikawa Y; Jingu K
Jpn J Radiol; 2019 Aug; 37(8):612-618. PubMed ID: 31201593
[TBL] [Abstract][Full Text] [Related]
14. Comparison of two different regimens of intravenous methylprednisolone for patients with moderate to severe and active Graves' ophthalmopathy: a prospective, randomized controlled trial.
He Y; Mu K; Liu R; Zhang J; Xiang N
Endocr J; 2017 Feb; 64(2):141-149. PubMed ID: 27853049
[TBL] [Abstract][Full Text] [Related]
15. Utility of T2 mapping in the staging of thyroid-associated ophthalmopathy: efficiency of region of interest selection methods.
Chen W; Hu H; Chen HH; Su GY; Yang T; Xu XQ; Wu FY
Acta Radiol; 2020 Nov; 61(11):1512-1519. PubMed ID: 32053002
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of combined orbital radiation and systemic steroids in the management of Graves' orbitopathy.
Kim JW; Han SH; Son BJ; Rim TH; Keum KC; Yoon JS
Graefes Arch Clin Exp Ophthalmol; 2016 May; 254(5):991-8. PubMed ID: 26876240
[TBL] [Abstract][Full Text] [Related]
17. Quantification of Global Ocular Motility Impairment in Graves' Orbitopathy by Measuring Eye Muscle Ductions.
Campi I; Currò N; Vannucchi G; Covelli D; Simonetta S; Fugazzola L; Dazzi D; Pignataro L; Guastella C; Lazzaroni E; Pirola G; Salvi M
Thyroid; 2021 Feb; 31(2):280-287. PubMed ID: 32940167
[No Abstract] [Full Text] [Related]
18. Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy.
Sisti E; Menconi F; Leo M; Profilo MA; Mautone T; Mazzi B; Rocchi R; Latrofa F; Nardi M; Vitti P; Marcocci C; Marinò M
J Endocrinol Invest; 2015 Jun; 38(6):661-8. PubMed ID: 25596664
[TBL] [Abstract][Full Text] [Related]
19. Correlation of signal intensity ratio on orbital MRI-TIRM and clinical activity score as a possible predictor of therapy response in Graves' orbitopathy--a pilot study at 1.5 T.
Kirsch EC; Kaim AH; De Oliveira MG; von Arx G
Neuroradiology; 2010 Feb; 52(2):91-7. PubMed ID: 19756565
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of tripterygium glycosides for active moderate to severe Graves' ophthalmopathy: a randomised, observer-masked, single-centre trial.
Ye X; Zhao H; Liu J; Lu B; Shao J; Wang J
Eur J Endocrinol; 2021 Feb; 184(2):277-287. PubMed ID: 33539318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
